ReviewCurrent treatment options in oncology2019
Cardiotoxicity of Contemporary Breast Cancer Treatments.
Review in Current treatment options in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Long-Term Side Effects of Breast Cancer Treatments: A Systematic Review.The breast journal · 2026Pooled it
- Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review.BMC cancer · 2022Pooled it
- Role of circular RNAs in regulating toxicity induced by cancer therapies.Genes & diseases · 2026Review
- Occult metastasis of hormone receptor-positive breast cancer to the ovary: A case report and literature review.Medicine · 2026Review
- Long-term cancer survivor awareness and learning preferences for cardio- oncologic risks: A qualitative study.Research square · 2026Article
- Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment.Oncology (Williston Park, N.Y.) · 2025Review
- Comprehensive review of non-invasive-treatment-related cardiovascular toxicity in breast cancer.iScience · 2025Review
- Machine learning based radiomics model to predict radiotherapy induced cardiotoxicity in breast cancer.Journal of applied clinical medical physics · 2025Article
- Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial.Journal of translational internal medicine · 2024Article
- Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities:JACC. CardioOncology · 2024Review
- Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study.BMC research notes · 2023Observational
- Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies.The Journal of experimental medicine · 2023Article
- Longitudinal Changes in Skeletal Muscle Metabolism, Oxygen Uptake, and Myosteatosis During Cardiotoxic Treatment for Early-Stage Breast Cancer.The oncologist · 2022Article
- Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy.Journal of oncology · 2022Article
- Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.Current heart failure reports · 2021Review
- Breast Cancer Survivors Undergoing Endocrine Therapy Have a Worrying Risk Factor Profile for Cardiovascular Diseases.Nutrients · 2021Article
- High intensity exercise during breast cancer chemotherapy - effects on long-term myocardial damage and physical capacity - data from the OptiTrain RCT.Cardio-oncology (London, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
opinion statementTreatment-related cardiotoxicity remains a significant concern for breast cancer patients undergoing cancer treatment and extends into the survivorship period, with adverse cardiovascular (CV) outcomes further compounded by the presence of pre-existing CV disease or traditional CV risk factors. Awareness of the cardiotoxicity profiles of contemporary breast cancer treatments and optimization of CV risk factors are crucial in mitigating cardiotoxicity risk. Assessment of patient- and treatment-specific risk with appropriate CV surveillance is another key component of care. Mismatch between baseline cardiotoxicity risk and intensity of cardiotoxicity surveillance can lead to unnecessary downstream testing, increased healthcare expenditure, and interruption or discontinuation of potentially life-saving treatment. Efforts to identify early imaging and/or circulating biomarkers of cardiotoxicity and develop effective management strategies are needed to optimize the CV and cancer outcomes of breast cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.